For the quarter ending 2026-03-31, CLDX had $6,858K increase in cash & cash equivalents over the period. -$67,227K in free cash flow.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -78,685 | -81,317 | -67,044 | -110,396 |
| Depreciation and amortization | 854 | 816 | 824 | 1,740 |
| Amortization and premium of marketable securities, net | 630 | 882 | 1,018 | 3,955 |
| Loss on sale or disposal of assets | -3 | 0 | -6 | -6 |
| Stock-based compensation expense | 8,523 | 8,909 | 8,801 | 18,507 |
| Accounts and other receivables | -1,785 | 1,925 | 0 | -610 |
| Prepaid and other current assets | -6,283 | -8,471 | 2,785 | -3,020 |
| Other assets | 2,076 | 3,994 | 64 | -447 |
| Accounts payable and accrued expenses | -287 | 4,601 | 13,062 | -6,632 |
| Other liabilities | -1,358 | 1,381 | -410 | -1,724 |
| Net cash used in operating activities | -65,588 | -63,940 | -48,628 | -98,377 |
| Sales and maturities of marketable securities | 133,366 | 111,500 | 116,915 | 367,873 |
| Purchases of marketable securities | 59,608 | 54,794 | 55,628 | 274,080 |
| Acquisition of property and equipment | 1,639 | 1,281 | 440 | 993 |
| Net cash provided by investing activities | 72,119 | 55,425 | 60,847 | 92,800 |
| Proceeds from issuance of stock from employee benefit plans | 327 | 1,349 | 774 | 265 |
| Net cash provided by financing activities | 327 | 1,349 | 774 | 265 |
| Net increase (decrease) in cash and cash equivalents | 6,858 | -7,166 | 12,993 | -5,312 |
| Cash and cash equivalents at beginning of period | 28,871 | 36,037 | 28,356 | - |
| Cash and cash equivalents at end of period | 35,729 | 28,871 | 36,037 | - |
Celldex Therapeutics, Inc. (CLDX)
Celldex Therapeutics, Inc. (CLDX)